This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look: Discussing the potential VX‑880, Vertex Pharmaceuticals' stem cell-derived pancreatic islet cell replacement therapy, for people with Type 1 Diabetes with impaired hypoglycemic awareness and severe hypoglycemia.

Ticker(s): VRTX

Who's the expert?

Institution: Columbia University

  • Physician-scientist with clinical and research focus in Type 2 Diabetes and related metabolic diseases. 
  • Board certified in Internal Medicine and fellowship in Endocrinology, Diabetes & Metabolism
  • Research focus on the role of developmental pathways in the regulation of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease, and the use of existing therapeutic agents in other scientific areas in novel applications to ameliorate obesity-induced complications including cancer. 

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.